Dual-agonist drugs targeting both GLP-1 and GIP receptors may produce greater weight loss than single GLP-1 agonists in patients who regain weight after bariatric surgery, but head-to-head trials are still needed.
Dual > SingleEarly studies suggest dual GLP-1/GIP agonists produce greater weight loss than single GLP-1 agonists alone in post-bariatric patients
What the researchers found
This comparative review found that single GLP-1 receptor agonists produce meaningful weight loss in patients who regain weight after bariatric surgery, while dual agonists targeting both GLP-1 and GIP receptors show even greater weight reduction in early studies.
However, the review emphasizes that post-surgical patients face unique challenges — including higher risk of micronutrient deficiencies, gastrointestinal intolerance, and maladaptive eating patterns — that require pharmacotherapy to be integrated with nutritional counseling, psychological support, and long-term multidisciplinary care.
Why it matters
Weight regain after bariatric surgery is a common and frustrating problem, affecting a significant portion of patients. This review maps out how newer peptide-based drugs — especially dual agonists like tirzepatide — could fill an important treatment gap, giving surgeons and patients a pharmacological safety net when surgery alone isn't enough.
How the study worked
Comparative narrative review of published studies on single (GLP-1 receptor agonist) and dual (GLP-1/GIP receptor agonist) pharmacotherapies in post-bariatric surgery patients experiencing insufficient weight loss or weight regain.
Who was studied
Post-bariatric surgery patients experiencing insufficient weight loss or weight regain
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, so the evidence synthesis is qualitative rather than quantitative. The review notes that dedicated head-to-head clinical trials comparing single vs. dual agonists specifically in post-bariatric populations are still lacking.
How to read the evidence
This is a narrative review synthesizing existing literature rather than presenting new primary data. While it provides a useful comparative overview, the lack of systematic methodology and the absence of direct head-to-head trials in post-bariatric populations limits the strength of its conclusions.
When this study was published
Published in 2026, this review covers the latest generation of obesity pharmacotherapies and is highly current.
The bigger picture
As GLP-1 drugs revolutionize obesity treatment, a key question is whether they can also rescue patients for whom surgery wasn't a permanent solution. This review positions dual agonists as the next frontier, while highlighting that the post-surgical body responds differently than a never-operated one — making dedicated trials essential before these drugs become standard post-op care.
Questions still open
- How do the gastrointestinal side effects of GLP-1 and dual agonist drugs differ in patients with surgically altered anatomy?
- Could long-term use of these drugs worsen micronutrient deficiencies already common after bariatric surgery?
- At what point after surgery should pharmacotherapy be introduced for optimal results?
Common questions
Can you take GLP-1 drugs like Ozempic or Wegovy after bariatric surgery?
Are dual-agonist drugs like tirzepatide better than single-agonist drugs for post-surgical weight regain?
Read the original research
Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review.
Nutrients, 18(4)
Citation
Reytor-González, Claudia; Campuzano-Donoso, Martín; Sarno, Gerardo; Montalvan, Martha; Horowitz, Raquel; Rossetti, Gianluca; Pilone, Vincenzo; Barrea, Luigi; Muscogiuri, Giovanna; Schiavo, Luigi; Simancas-Racines, Daniel. (2026). Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review.. Nutrients, 18(4). https://doi.org/10.3390/nu18040553